FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment

Accelerated approval (AA) by the FDA enables earlier access to promising new therapies. Health Canada has a similar process. Canada implemented a national health technology assessment (HTA) for reimbursement decisions in 2011. This study evaluated regulatory and funding timelines and decisions for F...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Cheryl, Lim, Howard J., Regier, Dean A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870743/
https://www.ncbi.nlm.nih.gov/pubmed/35200536
http://dx.doi.org/10.3390/curroncol29020036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870743/
https://www.ncbi.nlm.nih.gov/pubmed/35200536
http://dx.doi.org/10.3390/curroncol29020036

Ejemplares similares